Overall, data showed that darolutamide extended the time to deterioration in FACT-P total score (overall well-being). The median time to deterioration was 16.6 months in the darolutamide arm vs 11.5 ...

In a recent interview with Urology Times ®, David Stanley, MD, FACS, discussed current trends and unmet needs in the treatment of patients with kidney stones. Stanley is a urologic surgeon at Georgia ...

Key Takeaways Technological advancements in sacral neuromodulation include MRI-conditional devices, rechargeable systems, and extended battery lifespans, enhancing patient eligibility and reducing ...

Food-Drug Interactions and Absorption Considerations This segment provides crucial information about the significant impact of food on abiraterone absorption and the clinical implications for patient ...

Treatment of urgency urinary incontinence (UUI) with the Revi System was associated with clinically relevant and durable benefits in quality of life, according to 2-year data from the pivotal OASIS ...

Key Takeaways Illuccix's label expansion allows its use for selecting prostate cancer patients for PSMA-targeted RLT before taxane chemotherapy. The PSMAfore trial showed 177Lu-PSMA-617 significantly ...

Lymph Node Management and Molecular Imaging Main Discussion Topics: The current approach typically limits lymph node dissection to radiographically evident disease. Molecular imaging could identify ...

Clinical Decision-Making for Abiraterone Formulations This segment explores the practical considerations urologists face when selecting appropriate abiraterone formulations for individual patients ...

Overall, the phase 1/2 trial is assessing the safety and efficacy of the theranostic pair ITM-94/ITM-91 in identifying and treating patients with unresectable, locally advanced or metastatic solid ...

Complex Renal Masses and Molecular Imaging Main Discussion Topics: Challenges of managing anatomically complex renal masses Potential for molecular imaging to influence nephron-sparing decisions ...

There has been an explosion in innovation in the non–muscle invasive bladder cancer (NMIBC) space over the past few years. In an interview with Urology Times ®, Anne K. Schuckman, MD, detailed the ...

Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete ...